Xuyuan Zhang

Dr. Xuyuan Zhang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YZYujie Zou
Yujie Zou
JPJingwen Pei
Jingwen Pei
YWYushu Wang
Yushu Wang
QCQin Chen
Qin Chen
MSMinli Sun
Minli Sun
ZLZhaoyu Lin
Zhaoyu Lin
Deficiency in scavenger receptor class B, member 2 (SCARB2) is related to both Gaucher disease (GD) and Parkinson’s disease (PD), which are both neurodegenerative-related diseases without cure. Although both diseases lead to weight loss, which affects the quality of life and the progress of diseases, the underlying molecular mechanism is still unclear. In this study, we found that Scarb2−/− mice showed significantly reduced lipid storage in white fat tissues (WAT) compared to WT mice on a regular chow diet. However, the phenotype is independent of heat production, activity, food intake or energy absorption. Furthermore, adipocyte differentiation and cholesterol homeostasis were unaffected. We found that the impaired lipid accumulation of Adiponectin-cre; Scarb2fl/fl mice was due to the imbalance between glycolysis and oxidative phosphorylation (OXPHOS). Mechanistically, the mechanistic target of rapamycin complex 1 (mTORC1)/ eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) pathway was down-regulated in Scarb2 deficient adipocytes, leading to impaired mitochondrial respiration and enhanced glycolysis. Altogether, we reveal the role of SCARB2 in metabolism regulation besides the nervous system, which provides a theoretical basis for weight loss treatment of patients with neurodegenerative diseases.

26 August 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
ZYZhao Yin
Zhao Yin
XNXiaohua Nie
Xiaohua Nie
TLTianlun Li
Tianlun Li
BZBei Zhao
Bei Zhao
SWShouli Wang
Shouli Wang
ZSZhao-Liang SHAN
Zhao-Liang SHAN
Introduction: It has been reported Gas6/AXL pathway participates in several diseases. However, due of the lack of specific antibody, the significance and change circulatory Gas6/AXL complex in related diseases remain unclear.Methods: The mice were immunized with human AXL protein which were expressed by L cells to obtain monoclonal antibodies (mAbs). The flow cytometry was used to monoclonal antibodies screening and binding region mapping. To prepare an AXL-Gas6 specific mAb coated ELISA plate, and test the level of AXL-Gas6 complex in human blood.Results and discussion: We successfully obtained an AXL monoclonal antibody only binding to Gas6/AXL complex. Using the antibody, we firstly found that AXL expressed on human pDCs had bind to Gas6. Not only applicated in flow cytometry, this novel antibody could also be used as capture antibody in ELISA. Depend on this antibody, we firstly discovered that sAXL Gas6 complex was significantly increased in patients with AMI. Compared to AXL detected by commercial kit, AXL-Gas6 complex we measured emerged as a more sensitive biomarker and risk factor for patients with ST-segment elevation myocardial infarction.

17 April 2026 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
ZYZuming Yang
Zuming Yang
SCShuaishuai Cao
Shuaishuai Cao
JZJiaen Zhang
Jiaen Zhang
XNXiaohua Nie
Xiaohua Nie
ZWZhimin Wang
Zhimin Wang
YLYong Liang
Yong Liang
Immune-cold tumors fail to respond to immunotherapy due to insufficient lymphocyte infiltration within the tumor tissue. Increasing the objective response rate remains an urgent challenge. Here, we report the development of a monoclonal antibody (6C5) that specifically targets the membrane-proximal epitope of the receptor tyrosine kinase AXL and modulates antitumor immunity. Unlike traditional membrane-distal AXL antibodies, which suppress tumor growth primarily by blocking AXL signaling, 6C5 significantly enhanced innate immune sensing by promoting macrophage-mediated antigen uptake and type I interferon production. These effects further activated dendritic cells and increased CD8+ T-cell infiltration and effector function, thereby reshaping the tumor microenvironment. However, AXL antibody treatment concurrently induced a suppressive subset of PD-1hiFoxp3−CD4+ T cells. These cells displayed a transcriptomic profile resembling that of Tregs, characterized by elevated expression of immune checkpoint molecules (including PD-1 and CTLA4), reduced IL-2 production, and increased IL-2 receptor expression, thereby attenuating antitumor immune responses. The combination of 6C5 with dual immune checkpoint blockade (anti-PD-1 plus anti-CTLA-4) or a PD-1-targeted IL-2 fusion protein therapy mitigated this immunosuppression, resulting in potent tumor regression and durable immune memory. Our findings demonstrate that a membrane-proximal AXL-targeting antibody effectively converts the immune-cold tumor microenvironment, overcoming resistance to both conventional and next-generation immune checkpoint inhibitors.